ASCO University Weekly Podcasts

By ASCO University

Listen to a podcast, please open Podcast Republic app. Available on Google Play Store.


Category: Science & Medicine

Open in iTunes


Open RSS feed


Open Website


Rate for this podcast


Description

The ASCO University Weekly Podcast episodes focus on recent ASCO Guidelines, with discussion of the guideline's purpose, methods, results, and recommendations; newly approved drugs in oncology, outlining the drug uses, the type(s) of cancer the drug has been approved to to treat, how the drug is used, and any relevant clinical trials information; self-assessment questions sourced from various courses on ASCO University; and special episodes. The purpose of this podcast is to educate and to inform. This podcast is provided on the understanding that it does not constitute medical or other professional advice or services. It is no substitute for professional care by a doctor or other qualified medical professional and is not intended for use in the diagnosis or treatment of individual conditions. Guests who speak in this podcast express their own opinions, experience and conclusions. Neither American Society of Clinical Oncology nor any of its affiliates endorses, supports or opposes any particular treatment option or other matter discussed in this podcast. The mention of any product, service, organization, activity or therapy on the Podcast should not be construed as an ASCO endorsement.

Episode Date
Self-Evaluation: Breast - Partial Mastectomy Follow-Up
04:18

Rachel Freedman, MD, MPH- Assistant Professor, Medicine, Harvard Medical School, Dana-Farber Cancer Institute presents a self-assessment question from an ASCO University course focusing on the treatment breast cancer. 

AUDIO TRANSCRIPT

Welcome to the self-evaluation episode of the ASCO University weekly podcast. My name is Rachel Friedman, and I'm a medical oncologist and clinical researcher in the Breast Oncology Center at Dana-Farber Cancer Institute. Today, we feature a self-evaluation question on the treatment of early stage breast cancer. We begin by reading the question stem.

A 75-year-old woman with a past medical history of coronary artery disease and diabetes, with an ECOG performance status of 2, has been seen in the medical oncology office following a partial mastectomy for a 1 centimeter invasive breast cancer. The margins were clear and hormone receptors are reported as positive. The HER2/neu status is reported as negative. An Oncotype recurrence score is reported as 5.

Which of the following is the best adjuvant therapy for this patient? Choice A, doxorubicin, cyclophosphamide, and weekly paclitaxel, followed by an aromatase inhibitor. B, docetaxel and cyclophosphamide for four cycles, followed by an aromatase inhibitor for five years with radiation therapy to the breast. C, radiation therapy to the breast and axilla, followed by an aromatase inhibitor. D, aromatase inhibitor. E, tamoxifen.

The correct answer to this question is D, aromatase inhibitor. This patient has a poor performance status and high co-morbidity burden, with a higher likelihood of non-breast cancer deaths over breast cancer death, over time. The cancer is low risk, with a low likelihood for local and distant recurrence. Radiation and chemotherapy are unlikely to improve her outcome and will increase her toxicity risk. Further, we have multiple randomized trials to support safe omission of radiation and the setting of older age and stage 1 hormone receptor positive disease.

Briefly, the benefit of adjuvant chemotherapy is anticipated to be negligible, and even harmful, in the setting of her low risk disease, advanced co-morbidity, poor functional status, and Oncotype score of 5. Chemotherapy should be avoided in this setting, making answers A and B incorrect. Although radiation should be considered and administered in most patients with invasive breast cancer, undergoing breast conservation, as mentioned earlier, we have prospective randomized controlled trial data, supporting omission of radiation in this clinical scenario, making option C also incorrect for this reason.

Further, there is no indication for radiation to the axilla in a low risk breast cancer, such as the one described here, making option C incorrect for that reason as well. Option E, tamoxifen, is also a treatment option here, but may be less appealing in an older patient who lives a more sedentary lifestyle who may be at more risk for adverse events on tamoxifen, such as thrombosis, and where the use of aromatase inhibitors may be of a small incremental benefit over tamoxifen, with regard to risk for recurrences over time.

Thank you for listening to this week's episode of the ASCO University weekly podcast. For more information on the treatment of breast cancer, including opportunities for self-evaluation and for a review, please visit the comprehensive eLearning center at university.asco.org.

The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Aug 08, 2018
Special Episode: Non-Hodgkin Lymphoma
04:55

Karen M. Winkfield, MD, PhD, Associate Professor of Radiation Oncology, Comprehensive Cancer Center at Wake Forest Baptist Health discusses identifying factors associated with prognosis and staging in a MALT lymphoma and how to identify factors predicting local failure following H Pylori eradication therapy. 

Aug 01, 2018
Annual Meeting 2018 - ASCO Voices: The Call
14:16

2018 Annual Meeting raised the curtain on a new session type: ASCO Voices. These noncompete session feature presentations no longer than 7 minutes each and bring a variety of perspectives to the stage to share stories on oncology, medicine, and the world. From big ideas to personal passions, ASCO Voices present stories that differ significantly from the remainder of session types available at Annual Meeting.

Dr. Loehrer is director of the Indiana University Melvin and Bren Simon Cancer Center, an IU Distinguished Professor, H.H. Gregg Professor of Oncology and associate dean for cancer research at Indiana University School of Medicine

In his ASCO Voices presentation, Dr. Loehrer shares a personal story about coping with cancer diagnosis of a close colleague and friend.

 

 

Jul 25, 2018
Recently Approved Drugs: Lutetium Lu 177 dotatate for treatment of GEP-NETs
06:59

Dr. Jonathan Strosberg, section chief of the Neuroendocrine Tumor Division of the Moffitt Cancer Center, discusses the recent FDA approval of Lutetium Lu 177 dotatate for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Jul 18, 2018
ASCO Guideline: Antiemetics Guideline for Treatment-Induced Nausea and Vomiting
10:29

An interview with Dr. Paul Hesketh from Lahey Hospital and Medical Center on the antiemetics guideline update published in 2017. The guideline update expands the recommendations to include olanzapine and neurokinin 1 receptor antagonists. Read the full guideline at www.asco.org/supportive-care-guidelines

Jul 11, 2018
Self-Evaluation: Breast
04:08

Rachel Freedman, MD, MPH- Assistant Professor, Medicine, Harvard Medical School, Dana-Farber Cancer Institute, presents a self-assessment question from an ASCO University course focusing on the treatment breast cancer. 

 

Jul 03, 2018
Recently Approved Drugs: Durvalumab for patients with stage III Non-Small Cell Lung Cancers (NSCLC)
11:04

Rami Manochakian, M.D., a thoracic clinical oncologist at the Mayo Clinic in Florida, presents information on the recently approved drug in oncology, durvalumab for patients with stage III Non-Small Cell Lung Cancers (NSCLC) after the completion of radiation therapy.

Jun 27, 2018
Self-Evaluation: Special histologies - lymphoma: Primary CNS, appropriate first line therapy for newly diagnosed primary CNS lymphoma
04:36

Self-Evaluation: Karen M. Winkfield, MD, PhD, Associate Professor of Radiation Oncology, Comprehensive Cancer Center at Wake Forest Baptist Health, presents a self-assessment question from an ASCO University course focusing on, the appropriate first line therapy for newly diagnosed primary CNS lymphoma.

Jun 20, 2018
ASCO Guideline: Fertility Preservation in Patients with Cancer
12:56

An interview with Dr. Alison W. Loren of Perelman School of Medicine of the University of Pennsylvania on the ASCO guideline update which provides current recommendations about fertility preservation for adults and children with cancer. Read the full guideline at www.asco.org/survivorship-guidelines

Jun 13, 2018
Self-Evaluation: EGFR Mutation
04:44

Self-Evaluation: Apar Kishor Ganti, MD, Professor in the Department of Internal Medicine, Division of Oncology/Hematology, and Associate Director of Clinical Research at the Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, presents a self-evaluation question from an ASCO University course focusing on the treatment of an EGFR Mutation.

 

Jun 06, 2018
Recently Approved Drugs: Olaparib for germline BRCA-mutated metastatic breast cancer
05:18

Dr. Linh Alejandro, a clinical oncology pharmacist at the University of California, San Diego Health Systems discusses the approval of olaparib for germline BRCA-mutated metastatic breast cancer.

May 30, 2018
ASCO Guidelines: Outpatient Management of Fever and Neutropenia
11:20

An interview with Dr. Christopher Flowers of Emory University School of Medicine on the ASCO/IDSA clinical practice guideline which provides updated recommendations on outpatient management of fever and neutropenia in patients with cancer. Read the full guideline at www.asco.org/supportive-care-guidelines

May 23, 2018
Self-Evaluation: NSCLC Treatment Metastatic
06:11

Shadia Jalal, MD, Assistant Professor of Clinical Medicine Department of Medicine Division of Hematology/Oncology Indiana University School of Medicine, presents a self-evaluation question from an ASCO University course focusing on the treatment of non-small cell lung cancers.

May 16, 2018
Adjuvant Treatment in Melanoma: Recent Advances
06:40

Dr. Rodrigo Munhoz, medical oncologist at Centro de Oncologia- Hospital Sírio-Libanês in Sao Paolo, Brazil, discusses recent advances in the adjuvant therapy for patients with high-risk melanoma

May 09, 2018
Recently Approved Drugs: Blinatumomab for B-cell precursor ALL
05:05

Alex Ganetsky, PharmD, BCOP, oncology clinical pharmacy specialist at the Hospital of the University of Pennsylvania in Philadelphia discusses the approval to blinatumomab (Blincyto, Amgen Inc.) for the treatment of adult and pediatric patients with B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.

May 02, 2018
Guidelines: Management of Immune-Related Adverse Events
16:03

An interview with Dr. Bryan Schneider of the University of Michigan on the ASCO clinical practice guideline to increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events in patients treated with immune checkpoint inhibitor (ICPi) therapy. Read the full guideline at www.asco.org/supportive-care-guidelines 

Apr 25, 2018
Treatment Effects & Transition to Survivorship for AYA Patients
07:52

Cindy Schwartz, MD, MPH, is an accomplished oncologist who brings 35 years of experience, passion and expertise in the areas of Hodgkin lymphoma, osteosarcoma and childhood cancer survivorship.

Apr 18, 2018
EHR Chemotherapy Error: Breast Cancer
05:41

Dr. Carolyn Hendricks is a board certified medical oncologist specializing in breast cancer. She received her medical degree from Johns Hopkins University School of Medicine and has been in practice for more than 20 years. 

Apr 11, 2018
Continuity of Care for AYAs
05:28

Dr. Larissa Nekhlyudov is a board-certified general internist and Medical Director of Primary Care Associates, Longwood. Dr. Nekhlyudov practiced internal medicine at Harvard Vanguard Medical Associates for over 15 years. In this episode she discusses the importance of effective communication between the primary care physician & oncologist for AYA patients diagnosed with cancer.

Apr 04, 2018
Self-Evaluation: Clinical Trials Informed Consent Process
03:52

Dr. Suresh Ramalingam, professor of hematology and medical oncology at Emory University and Deputy Director at the Winship Cancer Institute of Emory University, presents a self-evaluation question on Clinical Trials: Informed Consent

Mar 28, 2018
Self-Evaluation: Clinical Trials
03:50

Dr. Suresh Ramalingam, professor of hematology and medical oncology at Emory University and Deputy Director at the Winship Cancer Institute of Emory University, presents a self-evaluation question on clinical research methodologies, clinical trials, phase III.

Mar 14, 2018
Self-Evaluation: NSCLC
03:55

Dr. Benjamin Levy, Clinical Director at the Johns Hopkins Sidney Kimmel Cancer Center at the Sibley Memorial Hospital in Washington, D.C., presents a self-evaluation questions on non-small cell lung cancer.

Feb 14, 2018
Self-Evaluation: Breast Cancer
04:31

Dr. Shaheenah Dawood, consultant medical oncologist and lead of the oncology research program at the Comprehensive Cancer Center Mediclinic City Hospital in the United Arab Emirates, presents a self-evaluation question on the predictive and prognostic rule of pathological complete response attained in the treatment of breast cancer.

Feb 07, 2018
Self-Evaluation: Metastatic Breast Cancer
03:50

Dr. Aditya Bardia, attending physician at the Massachusetts General Hospital Cancer Center, presents a self-evaluation question on the treatment of metastatic breast cancer.

Dec 13, 2017
ASCO Guidelines: Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer Update
05:28

Dr. Gregory Riely, medical oncologist at Memorial Sloan Kettering Cancer Center in New York City, presents the ASCO Guideline update on Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer, published in the Journal of Clinical Oncology in August 2017.

Dec 06, 2017
Recently Approved Drugs: Nivolumab for Metastatic Colorectal Cancer
08:12

Dr. Matthew Yurgelun, assistant professor of medicine at Harvard Medical School and gastrointestinal medical oncologist at the Dana Farber Gastrointestinal Cancer Center and Cancer Genetics and Prevention Program, presents information on the recently approved nivolumab for the treatment of patients 12 years and older with mismatch repair deficient and microsatellite instability high metastatic colorectal cancer.

Nov 22, 2017
Self-Assessment: Metastatic Prostate Cancer
03:39

Dr. Janice Dutcher, Associate Director of the Cancer Research Foundation of New York and medical oncology co-chair of the NCI Renal Cancer Task Force, presents a self-assessment question on the treatment of castrate-resistant metastatic prostate cancer.

Nov 15, 2017
ASCO Guidelines: Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer
07:51

Dr. Josh Lauring, Assistant Professor of Oncology at the Sidney Kimmel Cancer Center at John's Hopkins, presents the joint ASCO/AMP Guideline on Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in cancer, published in the Journal of Molecular Pathology in January 2017.

Nov 08, 2017
Recently Approved Drugs: Keytruda for cHL
05:12

Dr. Christina Wiedl, director of the pediatric and young adult stem cell transplant program at Virginia Commonwealth University, presents information on the recently approved drug in oncology, keytruda for relapsed and refractory classical Hodgkin lymphoma in pediatric and young adult patients.

Nov 01, 2017
Self-Assessment: NSCLC
03:44

Dr. Benjamin Levy, Clinical Director at the Johns Hopkins Sidney Kimmel Cancer Center at the Sibley Memorial Hospital in Washington, D.C., presents a self-assessment question on the diagnostic workup of a non-small cell lung cancer patient.

Oct 25, 2017
Special Episode: Survivorship in AYAs
06:36

Dr. Cindy Schwartz, Division Head of the Division of Pediatrics at the MD Anderson Cancer Center, discusses survivorship issues in treating adolescents and young adults with cancer. For more information, be sure to check out ASCO University's Survivorship Program on university.asco.org.

Oct 18, 2017
ASCO Guidelines: Management of Small Renal Masses
05:07

Dr. Ornob Roy, Urologist with Carolinas Healthcare Systems, presents the ASCO Guideline on Management of Small Renal Masses, originally published in the Journal of Clinical Oncology in January 2017.

Oct 11, 2017
Self-Assessment: Metastatic Melanoma
03:09

Dr. Janice Dutcher, Associate Director of the Cancer Research Foundation of New York and medical oncology co-chair of the NCI Renal Cancer Task Force, presents a self-assessment question on the treatment of metastatic melanoma.

Oct 04, 2017
Recently Approved Drugs: Olaratumab for Soft Tissue Sarcoma
04:50

Dr. William Tap, chief of the Sarcoma Medical Oncology Service at Memorial Sloan Kettering Cancer Center, presents information on the recently approved drug in oncology, olaratumab for soft tissue sarcoma.

Sep 27, 2017
ASCO Guidelines: Radiation Therapy for Glioblastoma
04:28

Dr. Steve Braunstein, radiation oncologist and assistant professor at the UCSF Medical Center at Mission Bay, presents the ASCO Guideline on Radiation Therapy for Glioblastoma, originally published in the Journal of Clinical Oncology in November 2016.

Sep 20, 2017
Self-Assessment: Hematologic Malignancies
03:01

Dr. Peter Wiernik, Director of the Cancer Research Foundation of New York and former chair of the Leukemia Committees of ECOG and CALGB, presents a self-assessment question on the differential diagnosis of certain hematologic malignancies.

Sep 13, 2017
New Drugs: Ribociclib for HER2-Negative Advanced or Metastatic Breast Cancer
05:04

Dr. Nina Karlin, medical oncologist and Assistant Professor of medicine at the Mayo Clinic Arizona, presents information on the newly approved drug in oncology, ribociclib for HER2-negative advanced or metastatic breast cancer.

Sep 06, 2017
ASCO Guidelines: HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma
05:26

Dr. Timothy Price, medical oncologist in Adelaide, Australia, presents the ASCO Guideline on HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma, originally published in the Journal of Clinical Oncology in February 2017.

Aug 30, 2017
Self-Assessment: Early Melanoma
02:50

Dr. Janice Dutcher, Associate Director of the Cancer Research Foundation of New York, presents a self-assessment question from an ASCO University course focusing on the treatment of early melanoma.

Aug 23, 2017
New Drugs: Niraparib for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer
05:04

Dr. Nina Karlin, medical oncologist and Assistant Professor of medicine at the Mayo Clinic Arizona, presents information on the newly approved drug in oncology, niraparib for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Aug 16, 2017
ASCO Guidelines: Potentially Curable Pancreatic Cancer
05:23

Dr. Alok Khorana, medical oncologist and professor of medicine at the Cleveland Clinic, presents the recently published ASCO Guideline on potentially curable pancreatic cancer.

Aug 09, 2017
Self-Assessment: Renal Cell Carcinoma
03:17

Dr. Janice Dutcher, Associate Director of the Cancer Research Foundation of New York and medical oncology co-chair of the NCI Renal Cancer Task Force, presents a self-assessment question on the treatment of renal cell carcinoma.

Aug 02, 2017
New Drugs: Osimertinib for Non-Small Cell Lung Cancer
05:13

Dr. Jared Weiss, Associate Professor at UNC-Chapel Hill Clinical Research and Thoracic Oncology Program, presents information on the recently approved drug in oncology, osimertinib for non-small cell lung cancer.

Jul 26, 2017
ASCO Guidelines: Secondary Prevention of Cervical Cancer
05:42

Dr. Philip Castle, Professor in the Department of Epidemiology and Population Health at Albert Einstein College of Medicine, presents the ASCO Guideline on Secondary Prevention of Cervical Cancer, originally published in the Journal of Clinic Oncology in October 2016.

Jul 19, 2017
Self-Assessment: Metastatic Lung Cancer in an Elderly Patient
03:40

Dr. Nina Karlin, medical oncologist and Assistant Professor of medicine at the Mayo Clinic Arizona, presents a self-assessment question on the treatment of metastatic lung cancer in an eldery patient.

Jul 12, 2017
New Drugs: Nivolumab for Hodgkin Lymphoma
05:20

Amitkumar Mehta, MD, Assistant Professor at the University of Alabama Birmingham School of Medicine, presents information on the recently approved drug in oncology, nivolumab for classical Hodgkin lymphoma.

Jul 05, 2017
ASCO Guidelines: Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers
05:16

Saro H. Armenian, D.O., MPH, pediatric hematologist/oncologist at City of Hope, presents the ASCO Guideline on prevention and monitoring of cardiac dysfunction in survivors of adult cancers, originally published in the Journal of Clinical Oncology in March 2017.

Jun 28, 2017
Special Episode: Communicating Prognosis to AYAs
08:38

In this special episode of the ASCO University Weekly Podcast series, Dr. Brad Zebrack, Professor of Social Work at the University of Michigan School of Social Work, presents information on communicating with adolescents and young adult patients in their family members regarding cancer care and diagnosis. For more information, be sure to visit the Communicating Prognosis course on ASCO University's comprehensive eLearning center and university.asco.org.

Jun 21, 2017
Self-Assessment: Breast Cancer in an Elderly Patient
03:31

Dr. Nina Karlin, medical oncologist and Assistant Professor of medicine at the Mayo Clinic Arizona, presents a self-assessment question on the treatment of breast cancer in an elderly patient.

Jun 14, 2017
New Drugs: Pembrolizumab for Non-Small Cell Lung Cancer
05:12

Dr. Alexander Drilon, Clinical Director of the Developmental Therapeutics Clinic and Assistant Attending Physician of the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center, presents information on the recently approved drug in oncology, pembrolizumab for non-small cell lung cancer.

Jun 07, 2017
ASCO Guidelines: Pancreatic Cancer
08:43

Dr. Edward Balaban, medical director of the Cancer Care Partnership at Penn State Health, presents the ASCO Clinical Practice Guideline on locally advanced, unresectable pancreatic cancer, originally published in the Journal of Clinical Oncology in August 2016.

May 31, 2017
Self-Assessment: Prostate Cancer
04:08

Nina Karlin, MD, Assistant Professor of Medicine at the Mayo Clinic in Arizona, presents a self-assessment question from an ASCO University course focusing on prostate cancer.

May 24, 2017
New Drugs: Venetoclax for Chronic Lymphocytic Leukemia
06:23

Prithviraj Bose, MD, Assistant Professor at the University of Texas MD Anderson Cancer Center Department of Leukemia, presents information on the recently approved drug in oncology, venetoclax for chronic lymphocytic leukemia.

May 17, 2017
ASCO Guidelines: Palliative Care
05:22

Betty Ferrell, PhD, MA, FAAN, FPCN, director of the Division of Nursing Research and Education and professor at City of Hope National Medical Center, presents the ASCO Guideline on Integration of Palliative Care into Standard Oncology Care, originally published in the Journal of Clinical Oncology in January 2017.

May 10, 2017
Self-Assessment: Testicular Cancer
05:14

Dr. Darren Feldman, medical oncologist specializing in the treatment of patients with genitourinary cancers at the Memorial Sloan Kettering Cancer Center, presents a self-assessment question from an ASCO University course focusing on the treatment of testicular cancer.

May 03, 2017
New Drugs: Rucaparib for Ovarian Cancer
03:21

Nina Karlin, M.D., Assistant Professor of Medicine at the Mayo Clinic in Arizona, presents information on the recently approved drug in oncology, rucaparib for ovarian cancer.

Apr 26, 2017
ASCO Guidelines: Pancreatic Cancer
05:24

Davendra Sohal, MD, MPH, Assistant Professor of Hematology and Medical Oncology at the Cleveland Clinic, presents the ASCO Clinical Practice Guideline on metastatic pancreatic cancer, originally published in the Journal of Clinical Oncology in August 2016.

Apr 19, 2017
Self-Assessment: Non-Small Cell Lung Cancer
04:37

Dr. Alexander Drilon, Clinical Director of the Developmental Therapeutics Clinic and Assistant Attending Physician of the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center, presents a self-assessment question from an ASCO University course focusing on the treatment of non-small cell lung cancers.

Apr 19, 2017
ASCO University Weekly Podcast Series
01:48

Welcome to the ASCO University Weekly Podcast! Dr. Alexander Drilon from Memorial Sloan Kettering Cancer Center provides a brief overview of what you can expect from the series. Be sure to subscribe for automatic updates on new episodes and visit university.asco.org for more from our comprehensive eLearning catalog.

Apr 19, 2017